Bifidobacterium adolescentis iVS-1: B. adolescentis iVS-1 (probiotic capsule) delivered orally once daily at a minimum of 8 billion CFU/day
Placebo: Placebo capsule delivered orally once daily
Study summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.
Eligibility
Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Aged 40-75 years.
* BMI: 20-34.9 kg/m².
* Able and willing to sign informed consent and participate for the study duration.
Exclusion Criteria:
* Chronic disease history (liver, kidney, heart).
* Current pregnancy and/or lactating.
* Colonoscopy and/or its preparation within 4 weeks of screening.
* Those who intend to have children during study period.
* Current probiotic, prebiotics and/or metabolic-altering supplement use.
* Those who are unable to cooperate with investigators and testing.
* Known history of cancer and/or ongoing cancer treatments.
* Abuse of drugs, alcohol, tobacco, nicotine and other substances.
* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.
* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.
* Type 1 or 2 diabetes mellitus.
* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.
* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.
* Significant weight loss (\>20%) in prior one month.
* Conditions affecting safety or outcome integrity.
Primary outcome measure(s)
Change in Biological Aging Biomarkers — Baseline to Day 150 Changes in gene expression of biomarkers associated with biological aging, assessed by quantitative polymerase chain reaction (qPCR), compared between placebo and study product groups over the study duration, including stratified analyses based on Bifidobacterium abundance.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.